Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19651
Title: Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging.
Authors: Elias, Alby;Cummins, Tia;Tyrrell, Regan;Lamb, Fiona;Dore, Vincent;Williams, Robert;Rosenfeld, Jeffrey;Hopwood, Malcolm;Villemagne, Victor L;Rowe, Christopher C
Affiliation: Department of Neurosurgery, Monash University, Victoria, Australia
Department of Psychiatry, The University of Melbourne, Victoria, Australia
CSIRO Brisbane, Queensland, Australia
Melbourne Brain Centre, Parkville, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: 8-Oct-2018
EDate: 2018-10-08
Citation: Journal of Alzheimer's disease : JAD 2018; online first: 8 October
Abstract: An association between obstructive sleep apnea (OSA) and Alzheimer's disease has been suggested but little is known about amyloid-β and tau deposition in this syndrome. To determine amyloid and tau burden and cognitive function in OSA in comparison to those without a diagnosis of OSA. The status of OSA was determined by asking participants about history of polysomnographic diagnosis of OSA and the use of Continuous Positive Airway Pressure (CPAP). A comprehensive neuropsychological battery measured cognitive function. Positron emission tomography (PET) was used to measure standardized uptake value ratio (SUVR) of 18F-florbetaben and 18F-AV1451, to quantify amyloid and tau burden. 119 male Vietnam veterans completed assessment. Impairment in visual attention and processing speed and increased body mass index (BMI) were seen in subjects with OSA compared with those without a diagnosis OSA. The cortical uptake of 18F-florbetaben was higher in the OSA group than in the control group (SUVR: 1.35±0.21 versus 1.27±0.16, p = 0.04). There were more apolipoprotein E ɛ4 allele (APOE ɛ4) carriers in the OSA group than in the control group. In multilinear regression analysis, the significance of OSA in predicting 18F-florbetaben uptake remained independent of age and vascular risk factors but not when BMI or APOE ɛ4 was adjusted. The reported use of CPAP (n = 14) had no effect on cognitive or amyloid PET findings. There was no significant difference in 18F-AV1451 uptake between the two groups. Obstructive sleep apnea is associated with Alzheimer's disease pathology, but this relationship is moderated by APOE ɛ4 and BMI.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19651
DOI: 10.3233/JAD-180640
ORCID: 0000-0003-3910-2453
PubMed URL: 30320587
Type: Journal Article
Subjects: Alzheimer’s disease
amyloid PET
dementia
obstructive sleep apnea
tau PET
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.